Last updated: May 25, 2026
SUFLAVE clinical trials update, market analysis, and projection (2026–2031)
Executive summary: SUFLAVE (balsalazide-disodium/rectal enema product) has not produced a well-documented, active late-stage clinical development program or a public FDA/Orange Book exclusivity profile that can be mapped to milestone dates, trial phase outcomes, and forecastable revenue. Without verifiable trial identifiers, dosing regimens, enrollment status, and commercialization datapoints tied to SUFLAVE specifically, a complete and accurate clinical update and market projection cannot be produced.
No data are available in the provided context to support:
- Trial phase status changes (Phase 1/2/3) and readouts for SUFLAVE.
- FDA pathway and approval history for SUFLAVE (NDA/BLA number, approval date, exclusivity).
- Patent/Orange Book listings and litigation that would affect launch timing.
- Current or historical sales/revenue base for SUFLAVE, or payer coverage signals.
- Market sizing anchored to SUFLAVE’s exact mechanism, dosage form, indication, and label claims.
What is SUFLAVE and what indication is it approved for?
No verifiable indication, formulation, strength, route, or regulatory identity for SUFLAVE is provided in the input. A clinical and commercial model depends on the approved label and the exact product.
Which active ingredient and delivery format does SUFLAVE use?
No SUFLAVE active ingredient details or dosage form are provided.
What therapeutic category does SUFLAVE compete in?
No confirmed therapeutic category is provided.
What clinical trials are active for SUFLAVE right now?
No trial identifiers, registries (e.g., NCT numbers), locations, recruiting status, or endpoints tied to SUFLAVE are provided.
Phase 1/2/3 status and readouts: what changed last 12 months?
No phase outcomes or timelines are provided.
Enrollment status, geography, and inclusion criteria
No inclusion criteria, target population, or enrollment status is provided.
How does SUFLAVE compare with competing therapies for the same indication?
No comparator set, mechanism of action, or approved alternatives are provided.
Which oral vs rectal formulations compete with SUFLAVE?
No formulation-specific competitive landscape is provided.
How do efficacy endpoints compare (clinical remission, endoscopic response, biomarker targets)?
No endpoints or comparative efficacy data are provided.
When does SUFLAVE lose exclusivity and what patent or exclusivity risks could delay generic entry?
No FDA approval identity or exclusivity basis is provided (e.g., 5-year New Chemical Entity, 7-year orphan, 3-year NDA supplemental exclusivity, pediatric exclusivity), and no Orange Book listings or patent numbers are provided.
What patents protect SUFLAVE on the Orange Book?
No Orange Book listing data is provided.
Are there Paragraph IV challenges affecting SUFLAVE launch timing?
No Paragraph IV or settlement/litigation records are provided.
What is the Orange Book status of SUFLAVE?
No Orange Book status (listed drug, patent list, expiration dates, exclusivity end dates) is provided.
What is SUFLAVE’s FDA regulatory status (NDA/BLA, approval date, supplements)?
No FDA submission identity or approval history is provided.
What market size can SUFLAVE capture and how fast could it grow?
No baseline sales, payer coverage, unit economics, or label scope is provided, preventing a credible demand model.
US vs ex-US revenue potential for SUFLAVE
No geographic launch plan or approvals are provided.
Pricing, reimbursement, and adoption curve assumptions
No pricing/reimbursement data are provided.
How do clinical outcomes translate into commercial adoption for SUFLAVE?
No trial efficacy/safety signals are provided that can be converted into market adoption scenarios.
Safety and tolerability profiles that affect formulary placement
No adverse event data are provided.
Endpoint-to-formulary linkage (remission vs symptom relief)
No endpoint data are provided.
SUFLAVE revenue projection (2026–2031): base, upside, downside scenarios
A revenue projection requires:
- The approved indication(s) and label wording.
- A credible addressable population and treatment penetration.
- Expected time to formulary adoption.
- Competition and loss-of-exclusivity timeline.
- Pricing assumptions and persistence.
None of these inputs are available in the provided context, so no accurate projection can be produced.
Key Takeaways
- A complete and accurate clinical trials update and market projection for SUFLAVE cannot be generated from the information provided.
- A defensible forecast requires verifiable SUFLAVE regulatory identity, trial registry details, endpoints, and commercialization datapoints, none of which are present here.
FAQs
- What clinical trial registry entries exist for SUFLAVE (NCT numbers, recruiting status, endpoints)?
- What is SUFLAVE’s FDA approval identity and date (NDA/BLA number, label indication)?
- Which patents and exclusivity periods are listed for SUFLAVE in the US Orange Book?
- What generic or biosimilar entry threats exist for SUFLAVE, including Paragraph IV filings?
- What are SUFLAVE’s expected market drivers (persistence, formulary adoption, payer restrictions)?
References
- (No sources were provided in the input; no citations can be generated.)
